Neuropace Inc
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable a… Read more
Neuropace Inc (NPCE) - Net Assets
Latest net assets as of September 2025: $18.52 Million USD
Based on the latest financial reports, Neuropace Inc (NPCE) has net assets worth $18.52 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($107.25 Million) and total liabilities ($88.74 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $18.52 Million |
| % of Total Assets | 17.27% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 8.45 |
Neuropace Inc - Net Assets Trend (2019–2024)
This chart illustrates how Neuropace Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Neuropace Inc (2019–2024)
The table below shows the annual net assets of Neuropace Inc from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $8.01 Million | -61.20% |
| 2023-12-31 | $20.65 Million | -40.61% |
| 2022-12-31 | $34.78 Million | -52.69% |
| 2021-12-31 | $73.50 Million | +149.72% |
| 2020-12-31 | $-147.83 Million | -14.29% |
| 2019-12-31 | $-129.35 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Neuropace Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16730900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $30.00K | 0.37% |
| Other Components | $538.93 Million | 6725.73% |
| Total Equity | $8.01 Million | 100.00% |
Neuropace Inc Competitors by Market Cap
The table below lists competitors of Neuropace Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ananti Inc
KQ:025980
|
$305.27 Million |
|
Xiamen Hexing Packaging Printing Co Ltd
SHE:002228
|
$305.31 Million |
|
Cosmoam&T
KO:005070
|
$305.37 Million |
|
SEMAPA SGPS NAM. O.N.
STU:SQQ1
|
$305.38 Million |
|
Chiyoda Corporation
PINK:CHYCF
|
$305.24 Million |
|
Suprajit Engineering Limited
NSE:SUPRAJIT
|
$305.19 Million |
|
Zhongfu Information Inc
SHE:300659
|
$305.16 Million |
|
ECOVE Environment Corp
TWO:6803
|
$305.16 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Neuropace Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 20,654,000 to 8,013,000, a change of -12,641,000 (-61.2%).
- Net loss of 27,141,000 reduced equity.
- New share issuances of 3,277,000 increased equity.
- Other factors increased equity by 11,223,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-27.14 Million | -338.71% |
| Share Issuances | $3.28 Million | +40.9% |
| Other Changes | $11.22 Million | +140.06% |
| Total Change | $- | -61.20% |
Book Value vs Market Value Analysis
This analysis compares Neuropace Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 50.23x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-11.65 | $13.82 | x |
| 2020-12-31 | $-13.31 | $13.82 | x |
| 2021-12-31 | $4.43 | $13.82 | x |
| 2022-12-31 | $1.41 | $13.82 | x |
| 2023-12-31 | $0.80 | $13.82 | x |
| 2024-12-31 | $0.28 | $13.82 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Neuropace Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -338.71%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -33.97%
- • Asset Turnover: 0.84x
- • Equity Multiplier: 11.81x
- Recent ROE (-338.71%) is below the historical average (-113.79%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -81.07% | 1.75x | 0.00x | $-17.04 Million |
| 2020 | 0.00% | -59.02% | 0.74x | 0.00x | $-9.49 Million |
| 2021 | -49.09% | -79.85% | 0.34x | 1.82x | $-43.43 Million |
| 2022 | -135.38% | -103.43% | 0.40x | 3.28x | $-50.56 Million |
| 2023 | -159.56% | -50.38% | 0.61x | 5.21x | $-35.02 Million |
| 2024 | -338.71% | -33.97% | 0.84x | 11.81x | $-27.94 Million |
Industry Comparison
This section compares Neuropace Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Neuropace Inc (NPCE) | $18.52 Million | 0.00% | 4.79x | $305.25 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |